Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.09
TEVA's Cash to Debt is ranked lower than
59% of the 750 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. TEVA: 0.09 )
TEVA' s 10-Year Cash to Debt Range
Min: 0.08   Max: 1.03
Current: 0.09

0.08
1.03
Equity to Asset 0.48
TEVA's Equity to Asset is ranked higher than
54% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.60 vs. TEVA: 0.48 )
TEVA' s 10-Year Equity to Asset Range
Min: 0.4   Max: 0.59
Current: 0.48

0.4
0.59
Interest Coverage 5.25
TEVA's Interest Coverage is ranked higher than
50% of the 460 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 88.77 vs. TEVA: 5.25 )
TEVA' s 10-Year Interest Coverage Range
Min: 3.6   Max: 328.25
Current: 5.25

3.6
328.25
F-Score: 6
Z-Score: 1.69
M-Score: -2.67
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 8.12
TEVA's Operating margin (%) is ranked higher than
71% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.34 vs. TEVA: 8.12 )
TEVA' s 10-Year Operating margin (%) Range
Min: 8.12   Max: 26.78
Current: 8.12

8.12
26.78
Net-margin (%) 6.25
TEVA's Net-margin (%) is ranked higher than
69% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. TEVA: 6.25 )
TEVA' s 10-Year Net-margin (%) Range
Min: 5.73   Max: 21.09
Current: 6.25

5.73
21.09
ROE (%) 5.62
TEVA's ROE (%) is ranked higher than
68% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. TEVA: 5.62 )
TEVA' s 10-Year ROE (%) Range
Min: 3.9   Max: 22.43
Current: 5.62

3.9
22.43
ROA (%) 2.67
TEVA's ROA (%) is ranked higher than
67% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.94 vs. TEVA: 2.67 )
TEVA' s 10-Year ROA (%) Range
Min: 1.93   Max: 11.68
Current: 2.67

1.93
11.68
ROC (Joel Greenblatt) (%) 18.01
TEVA's ROC (Joel Greenblatt) (%) is ranked higher than
78% of the 732 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.50 vs. TEVA: 18.01 )
TEVA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 12.03   Max: 47.4
Current: 18.01

12.03
47.4
Revenue Growth (%) 10.90
TEVA's Revenue Growth (%) is ranked higher than
75% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. TEVA: 10.90 )
TEVA' s 10-Year Revenue Growth (%) Range
Min: 10.2   Max: 23.4
Current: 10.9

10.2
23.4
EBITDA Growth (%) -10.40
TEVA's EBITDA Growth (%) is ranked higher than
57% of the 507 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. TEVA: -10.40 )
TEVA' s 10-Year EBITDA Growth (%) Range
Min: -10.4   Max: 47.2
Current: -10.4

-10.4
47.2
EPS Growth (%) -25.60
TEVA's EPS Growth (%) is ranked higher than
52% of the 510 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. TEVA: -25.60 )
TEVA' s 10-Year EPS Growth (%) Range
Min: -25.6   Max: 69.8
Current: -25.6

-25.6
69.8
» TEVA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

TEVA Guru Trades in Q2 2013

Diamond Hill Capital 103,665 sh (+122.79%)
Caxton Associates 62,300 sh (+95.91%)
Pioneer Investments 762,471 sh (+52.99%)
Manning & Napier Advisors, Inc 251,518 sh (+32.17%)
David Dreman 155,293 sh (+12.99%)
NWQ Managers 6,778,539 sh (+11.17%)
Richard Snow 1,365,474 sh (+6.84%)
Tom Gayner 699,000 sh (+5.33%)
Louis Moore Bacon 150,000 sh (unchged)
Bernard Horn 52,800 sh (unchged)
Vanguard Health Care Fund 11,361,300 sh (unchged)
Michael Price 350,000 sh (unchged)
Jean-Marie Eveillard 200 sh (unchged)
Meryl Witmer 22,400 sh (unchged)
George Soros Sold Out
James Barrow 6,723,966 sh (-5.01%)
Ronald Muhlenkamp 169,660 sh (-41.05%)
Jim Simons 298,363 sh (-82.68%)
Steven Cohen 11,099 sh (-90.84%)
» More
Q3 2013

TEVA Guru Trades in Q3 2013

George Soros 3,608,000 sh (New)
Murray Stahl 9,460 sh (New)
Diamond Hill Capital 264,149 sh (+154.81%)
Steven Cohen 15,918 sh (+43.42%)
Vanguard Health Care Fund 13,145,600 sh (+15.71%)
Pioneer Investments 851,378 sh (+11.66%)
David Dreman 164,964 sh (+6.23%)
Richard Snow 1,427,022 sh (+4.51%)
Manning & Napier Advisors, Inc 254,956 sh (+1.37%)
James Barrow 6,759,766 sh (+0.53%)
Ronald Muhlenkamp 169,985 sh (+0.19%)
Tom Gayner 700,000 sh (+0.14%)
Bernard Horn 52,800 sh (unchged)
Michael Price 350,000 sh (unchged)
Jean-Marie Eveillard 200 sh (unchged)
Jim Simons Sold Out
Caxton Associates Sold Out
NWQ Managers 6,132,913 sh (-9.52%)
» More
Q4 2013

TEVA Guru Trades in Q4 2013

Stanley Druckenmiller 1,241,000 sh (New)
Alan Fournier 130,000 sh (New)
Caxton Associates 42,900 sh (New)
George Soros 9,316,000 sh (+158.2%)
James Barrow 12,143,563 sh (+79.64%)
Murray Stahl 13,902 sh (+46.96%)
Richard Snow 1,976,831 sh (+38.53%)
Diamond Hill Capital 348,631 sh (+31.98%)
Michael Price 400,000 sh (+14.29%)
Ronald Muhlenkamp 176,340 sh (+3.74%)
Jean-Marie Eveillard 200 sh (unchged)
Vanguard Health Care Fund 13,145,600 sh (unchged)
Bernard Horn 52,800 sh (unchged)
George Soros 1,425,000 sh (unchged)
Tom Gayner 699,900 sh (-0.01%)
NWQ Managers 5,992,360 sh (-2.29%)
Manning & Napier Advisors, Inc 231,489 sh (-9.2%)
David Dreman 147,328 sh (-10.69%)
Steven Cohen 12,509 sh (-21.42%)
Pioneer Investments 78,418 sh (-90.79%)
» More
Q1 2014

TEVA Guru Trades in Q1 2014

Manning & Napier Advisors, Inc 231,252 sh (-0.1%)
» More
» Details

Insider Trades

Latest Guru Trades with TEVA

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2013-12-31 Add 158.2%1.96%$36.59 - $41.7 $ 50.6729%9316000
James Barrow 2013-12-31 Add 79.64%0.31%$36.59 - $41.7 $ 50.6729%12143563
Michael Price 2013-12-31 Add 14.29%0.26%$36.59 - $41.7 $ 50.6729%400000
George Soros 2013-09-30 New Buy1.5%$37.43 - $41.27 $ 50.6730%3608000
Vanguard Health Care Fund 2013-09-30 Add 15.71%0.23%$37.43 - $41.27 $ 50.6730%13145600
Ronald Muhlenkamp 2013-06-30 Reduce -41.05%0.99%$37.8 - $40.23 $ 50.6730%169660
George Soros 2013-06-30 Sold Out 0.02%$37.8 - $40.23 $ 50.6730%0
Vanguard Health Care Fund 2013-03-31 Add 13.37%0.21%$37.19 - $41.06 $ 50.6731%11361300
James Barrow 2013-03-31 Add 64.42%0.2%$37.19 - $41.06 $ 50.6731%7078456
John Burbank 2013-03-31 Sold Out 0.11%$37.19 - $41.06 $ 50.6731%0
George Soros 2013-03-31 Reduce -66.67%0.04%$37.19 - $41.06 $ 50.6731%50000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Teva Pharmaceutical Industries Ltd

Groups of Gurus Trade Ten-Year Low P/B Stocks - CLH, IMO and TEVA
According to the GuruFocus Value Screen that shows value strategies of stocks traded at historical low P/B ratios, Teva Pharmaceutical Industries Ltd. (TEVA), Imperial Oil Ltd (IMO) and Clean Harbors Inc. (CLH) are held by numerous gurus and trading near their 10-year low. Here are the company updates and trading highlights as of the third quarter of 2013. Read more...
Bargain Hunting with Phenom Michael Price for 52-Week Lows
Guru Michael Price of MFP Investors LLC is a self-made investing phenom averaging a 12-month return of 84.84%. Over 12 months, Price is the fourth highest returning guru, following John Paulson at 296.45%, Michael Dell at 270.13% and Robert Karr at 89.84%. Read more...
Top Five Guru-Held Asian Companies as of the Second Quarter
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies maintain the highest amount of guru ownership. By using this screener, we filtered down to see which companies based in Asian countries were held by the highest number of gurus. The following five companies come from a variety of industries, are Asian-based and are held by the largest number of gurus. [b] Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 33.80
TEVA's P/E(ttm) is ranked higher than
57% of the 528 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.60 vs. TEVA: 33.80 )
TEVA' s 10-Year P/E(ttm) Range
Min: 10.53   Max: 1072.29
Current: 33.8

10.53
1072.29
P/B 1.90
TEVA's P/B is ranked higher than
75% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.84 vs. TEVA: 1.90 )
TEVA' s 10-Year P/B Range
Min: 1.37   Max: 7
Current: 1.9

1.37
7
P/S 2.12
TEVA's P/S is ranked higher than
67% of the 722 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.99 vs. TEVA: 2.12 )
TEVA' s 10-Year P/S Range
Min: 1.58   Max: 5.94
Current: 2.12

1.58
5.94
PFCF 24.96
TEVA's PFCF is ranked higher than
68% of the 330 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.86 vs. TEVA: 24.96 )
TEVA' s 10-Year PFCF Range
Min: 9.63   Max: 65.51
Current: 24.96

9.63
65.51
EV-to-EBIT 36.31
TEVA's EV-to-EBIT is ranked lower than
56% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.45 vs. TEVA: 36.31 )
TEVA' s 10-Year EV-to-EBIT Range
Min: 11.7   Max: 990.4
Current: 36.31

11.7
990.4
PEG 1.80
TEVA's PEG is ranked higher than
76% of the 312 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.74 vs. TEVA: 1.80 )
TEVA' s 10-Year PEG Range
Min: 0.43   Max: 116.41
Current: 1.8

0.43
116.41
Shiller P/E 21.57
TEVA's Shiller P/E is ranked higher than
70% of the 362 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.59 vs. TEVA: 21.57 )
TEVA' s 10-Year Shiller P/E Range
Min: 14.08   Max: 78.77
Current: 21.57

14.08
78.77

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.20
TEVA's Dividend Yield is ranked higher than
77% of the 419 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.38 vs. TEVA: 2.20 )
TEVA' s 10-Year Dividend Yield Range
Min: 0.16   Max: 2.76
Current: 2.2

0.16
2.76
Dividend Payout 0.73
TEVA's Dividend Payout is ranked lower than
63% of the 367 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. TEVA: 0.73 )
TEVA' s 10-Year Dividend Payout Range
Min: 0.05   Max: 0.73
Current: 0.73

0.05
0.73
Dividend growth (3y) 17.60
TEVA's Dividend growth (3y) is ranked higher than
89% of the 236 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.50 vs. TEVA: 17.60 )
TEVA' s 10-Year Dividend growth (3y) Range
Min: -6.7   Max: 80.9
Current: 17.6

-6.7
80.9
Yield on cost (5-Year) 5.45
TEVA's Yield on cost (5-Year) is ranked higher than
93% of the 430 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.42 vs. TEVA: 5.45 )
TEVA' s 10-Year Yield on cost (5-Year) Range
Min: 0.4   Max: 6.84
Current: 5.45

0.4
6.84
Share Buyback Rate 2.60
TEVA's Share Buyback Rate is ranked higher than
93% of the 483 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -2.70 vs. TEVA: 2.60 )
TEVA' s 10-Year Share Buyback Rate Range
Min: 2.6   Max: -10.9
Current: 2.6

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 0.81
TEVA's Price/DCF (Projected) is ranked higher than
92% of the 346 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. TEVA: 0.81 )
TEVA' s 10-Year Price/DCF (Projected) Range
Min: 0.59   Max: 7.35
Current: 0.81

0.59
7.35
Price/Median PS Value 0.61
TEVA's Price/Median PS Value is ranked higher than
92% of the 665 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.10 vs. TEVA: 0.61 )
TEVA' s 10-Year Price/Median PS Value Range
Min: 0.46   Max: 1.59
Current: 0.61

0.46
1.59
Price/Peter Lynch Fair Value 2.38
TEVA's Price/Peter Lynch Fair Value is ranked lower than
51% of the 145 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.50 vs. TEVA: 2.38 )
TEVA' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.58   Max: 12.09
Current: 2.38

0.58
12.09
Earnings Yield (Greenblatt) 2.80
TEVA's Earnings Yield (Greenblatt) is ranked higher than
52% of the 595 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. TEVA: 2.80 )
TEVA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 8.6
Current: 2.8

0.1
8.6
Forward Rate of Return (Yacktman) 18.68
TEVA's Forward Rate of Return (Yacktman) is ranked higher than
88% of the 532 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.45 vs. TEVA: 18.68 )
TEVA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 6.5   Max: 37.4
Current: 18.68

6.5
37.4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, AGN, FRX, MRX, ESALF » details
Traded in other countries:TEVJF.USA, TEV.Germany
Teva Pharmaceutical Industries Ltd develops, produces and markets generic, branded & OTC medicines. Some of its products are Copaxone, Azilect & Provigil.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide